Scarica l'app Stockscreener
11.91
3.12%
0.36
Urogen Pharma Ltd Azioni (URGN) Dati Finanziari
Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
| Data di fine periodo | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| Durata del periodo | 3 mesi | 3 mesi | 3 mesi | 3 mesi | 3 mesi |
| Revenues |
20.18%
18.78
|
23.53 | 20.85 | 21.14 | 17.19 |
| Cost Of Revenue |
24.41%
1.728
|
2.286 | 2.367 | 2.443 | 2.265 |
| Gross Profit |
19.73%
17.05
|
21.24 | 18.48 | 18.70 | 14.93 |
Operating Expenses
|
19.36%
42.79
|
35.85 | 31.98 | 34.08 | 36.97 |
| Benefits Costs and Expenses |
11.65%
51.01
|
45.69 | 42.74 | 45.22 | 47.38 |
| Costs And Expenses |
11.65%
51.01
|
45.69 | 42.74 | 45.22 | 47.38 |
| Operating Income/Loss |
76.19%
-25.74
|
-14.61 | -13.50 | -15.38 | -22.05 |
| Nonoperating Income/Loss |
122.54%
-0.183
|
0.812 | 0.071 | -0.03 | -0.015 |
| Income/Loss From Continuing Operations Before Tax |
45.44%
-32.23
|
-22.16 | -21.89 | -24.08 | -30.19 |
| Income Tax Expense/Benefit |
98.60%
0.054
|
3.854 | -0.009 | 0.054 | 0.021 |
| Income/Loss From Continuing Operations After Tax |
24.10%
-32.29
|
-26.02 | -21.88 | -24.14 | -30.21 |
|
Net Income/Loss
|
24.10%
-32.29
|
-26.02 | -21.88 | -24.14 | -30.21 |
| Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
1,248%
33.38
|
2.4756 | 32.30 | 23.46 | 23.28 |
| Basic Earnings Per Share |
46.97%
-0.97
|
-0.66 | -0.68 | -1.03 | -1.30 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):